Reference

Inositol phospholipid-induced suppression of F-actin-gelating activity of smooth muscle filamin

Inositol phospholipid-induced suppression of F-actin-gelating activity of smooth muscle filamin. Furuhashi, Kiyoshi; Inagaki, Masaki; Hatano, Sadashi; Fukami, Kiyoko; Takenawa, Tadaomi (Aichi Cancer Cent., Res. Inst., Nagoya 464, Japan). Biochem. Biophys. Res. Commun., 184(3), 1261-5 (English) 1992. CODEN: BBRCA9. ISSN: 0006-291X. DOCUMENT TYPE: Journal CA Section: 6 (General Biochemistry) Section cross-reference(s): 12 Filamin, a high-mol.-wt. actin-binding protein, cross-links actin filaments and produces a gel composed of F-actin. The effects of polyphosphoinositides on the gelating activity of smooth muscle filamin were examd. by measuring the low shear viscosity of the F-actin solns. contg. filamin incubated with phosphatidylinositol (PI), phosphatidylinositol 4-monophosphate (PIP), or phosphatidylinositol 4,5-bisphosphate (PIP2). Micelles of these inositol phospholipids bound to filamin inhibited the ability to form a gel of F-actin. The inhibiting activity of each phospholipid was in the following order, PIP2 > PIP > PI. The F-actin binding assay of filamin revealed that the inhibition of F-actin-gelation resulted in the loss of the F-actin-binding activity of filamin. Thus, polyphosphoinositides may play important roles in regulating the gelating activity of filamin.

Gene expression and multiple sclerosis

Gene expression and multiple sclerosis. Griffiths, Lynette Robyn; Tajouri, Lotti (Griffith University, Australia). PCT Int. Appl. WO 2003102227 A1 11 Dec 2003, 80 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C12Q001-68. ICS: G01N033-53. APPLICATION: WO 2003-AU684 2 Jun 2003. PRIORITY: AU 2002-2719 31 May 2002. DOCUMENT TYPE: Patent CA Section: 14 (Mammalian Pathological Biochemistry) Section cross-reference(s): 3 Genes and encoded proteins that are differentially expressed in cells and tissues of individuals suffering from multiple sclerosis compared to cells and tissues of non-sufferers are provided. Examples of these genes include Serum Transferrin; RNase pancreatic precursor; Eucaryotic translation elongation factor 1, alpha 1; Guanine nucleotide binding protein; Glutathione peroxidase 1; SLC10A1; Calpain subunit 1; Inositol 1,4,5 triphosphate 3 kinase B; Peripheral myelin Protein 22; Mal (T cell differentiation Protein); CRYAB Crystallin, alpha B; Betaine-Homocysteine Me transferase; ADP-ribosylation factor 5; Glutathione S-transferase; Phosphomannomutase-1; Tubulin beta 5; Ubiquitin A-52 residue ribosomal protein factor product 1; SOD1 Superoxide dismutase 1; CST3 Cystatin C protease inhibitor; Small nuclear ribonucleoprotein polypeptide N; and Solute carrier 25. Genes of the invention may, at least in some cases, carry mutations or other sequence variations that affect gene expression and contribute to multiple sclerosis pathophysiol. These genes may be of diagnostic value in predicting a predisposition to multiple sclerosis, confirming clin. diagnosis of multiple sclerosis and in the discovery of compds. for use in treating multiple sclerosis.